Objectives: Nanobodies, the single domain antigen binding fragments of heavy chain-only antibodies occurring naturally in camelid sera, are the smallest intact antigen binding entities. Their minimal size assists in reaching otherwise largely inaccessible regions of antigens. However, their camelid origin raises a possible concern of immunogenicity when used for human therapy. Humanization is a promising approach to overcome the problem.

Materials and Methods: Here, we designed a humanized version of previously developed nanobody (anti vascular endothelial growth factor nanobody), evaluated and compared its predicted 3D structure, affinity and biological activity with its original wild type nanobody.

Results: Ourin silicoresults revealed an identical 3D structure of the humanized nanobody as compare to original nanobody.In vitrostudies also demonstrated that the humanization had no significant visible effect on the nanobody affinity or on its biological activity.

Conclusion: The humanized nanobody could be developed and proposed as a promising lead to target pathologic angiogenesis.

Original languageEnglish
Pages (from-to)260-266
Number of pages7
JournalIranian Journal of Basic Medical Sciences
Issue number3
Publication statusPublished - 1 Mar 2018

    Research areas

  • Angiogenesis, Antibody engineering, Humanization, Nanobody, VEGF

ID: 36937867